Recent Quotes (30 days)

You have no recent quotes
chg | %

Antisense Therapeutics Limited  

(Public, ASX:ANP)   Watch this stock  
Find more results for ASX: ANP
0.0320
0.0000 (0.00%)
Oct 18 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range     -
52 week 0.03 - 0.06
Open     -
Vol / Avg. 0.00/15,601.00
Mkt cap 5.65M
P/E     -
Div/yield     -
EPS -0.02
Shares 161.56M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin -1459.42% -1965.33%
Operating margin -1456.74% -1960.01%
EBITD margin - -1956.52%
Return on average assets -87.27% -70.04%
Return on average equity -108.72% -85.68%
Employees 8 -
CDP Score - -

Address

6 Wallace Ave
MELBOURNE, VIC 3142
Australia
+61-3-98278999 (Phone)
+61-3-98271166 (Fax)

Website links

Description

Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery and development company. The Company is engaged in the research and development of antisense pharmaceuticals. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly, diabetic retinopathy and diabetic nephropathy. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company's product candidate, ATL1101, is an antisense inhibitor of insulin like growth factor 1 receptor (IGF-Ir). It is developing ATL1101 for the treatment of prostate cancer. It is also developing ATL1102 as an inhaled treatment for asthma.

Officers and directors

Phillip Hains Chief Financial Officer, Company Secretary
Mark Diamond Managing Director, Executive Director
George Tachas Ph.D. Director - Drug Discovery & Patents
Robert W. Moses Independent Non-Executive Chairman of the Board
William A. Goolsbee Non-Executive Director
Age: 62
Gary Pace Ph.D. Non-Executive Director
Age: 69
Graham F. Mitchell Independent Non-Executive Director
Age: 72